Can-Fite BioPharma (CANF) announced that a patient currently treated with Namodenoson in a compassionate use program in Can-Fite’s Phase II Liver Cancer Study has an overall survival time of 8 years with a complete response. The patient, who suffered from advanced liver cancer was enrolled in the former Can-Fite Phase II study, continue to be treated with Namodenoson, and has now an overall survival of 8 years, with disappearance of ascites, normal liver function, good quality of life and is defined as a long term complete response.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- CANF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Can-Fite BioPharma Advances in Pancreatic Cancer Trial
- Can-Fite BioPharma doses first patient in Phase IIa trial
- Can-Fite BioPharma Secures Australian Patent for Obesity Drug
- Can-Fite BioPharma announces an update related to IP status of Namodenoson